Prestige Biologics프레스티지바이오로직스
334970 · KOSDAQ · ₩334970 · 프레스티지바이오로직스
₩1,166▼ ₩65 (5.28%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | −125.2% | −125.2% | −400.5% | 29.9% | 23.1% | 73.0% |
| Operating margin | −268.7% | −268.7% | −1,541.2% | −1,277.6% | −235,333.1% | −831.7% |
| Net margin | −219.2% | −219.2% | −1,354.2% | −1,039.1% | −319,406.8% | −1,220.3% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +477.8% | +477.8% | +25.4% | +11,015.9% | −99.5% | — |
| Operating income growth | −0.8% | −0.8% | −51.2% | +39.7% | −36.5% | — |
| Net income growth | +6.5% | +6.5% | −63.4% | +63.8% | −26.3% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −26.6% | −26.6% | −34.3% | −16.5% | −44.3% | −36.9% |
| Return on assets | −9.8% | −9.8% | −9.9% | −6.4% | −21.4% | −19.0% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 99.9% | 99.9% | 303.7% | 206.4% | 119.4% | 93.5% |
| Net debt to equity | 66.5% | 66.5% | 200.1% | 114.8% | 87.7% | 38.5% |
| Current ratio | 39.9% | 39.9% | 60.3% | 78.8% | 91.7% | 193.2% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Prestige Biologics / 프레스티지바이오로직스 / 334970 / KRX:334970
Source: KRX statistical information